Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of BHV-0223 in Subjects With Amyotrophic Lateral Sclerosis
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2018
Price : $35 *
At a glance
- Drugs Riluzole (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Biohaven Pharmaceutical
- 21 Nov 2018 Status changed from active, no longer recruiting to completed.
- 23 Jul 2018 Planned End Date changed from 31 Jul 2018 to 31 Oct 2018.
- 23 Jul 2018 Planned primary completion date changed from 31 Jul 2018 to 31 Oct 2018.